The concept of gene therapy was introduced by Friedmann and Roblin back in 1972. 172 ZFN (zinc finger nucleases) and TALEN (transcription activator-like effector nucleases) were then developed as mainstream tools to evaluate the possibility of targeting or editing genes to cure diseases. . Both these methods require complex design strategies and can tolerate only a small number of positional mismatches making development of successful and effective gene therapy challenging. With ZFN, it is difficult to target non-G-rich sites and for each TALEN monomer, 5' targeted base must be a T. Later, CRISPR/Cas emerged as a new tool to edit genes and since its discovery, it has been explored tremendously by researchers as a potential therapeutic approach for disorders which were previously thought to be incurable or difficult to cure. These include certain types of cancers, infectious diseases, and various genetic disorders, among others. CRISPR/CAS is beneficial over earlier conventional gene therapy methods such as ZFN and TALENs as it is easy to engineer and can tolerate positional/multiple consecutive mismatches. CRISPR/Cas technology has various key applications in the field of therapeutics, the most apparent of which would be to correct or replace the mutated or disease-causing gene(s). CRISPR/Cas based gene therapy can be delivered in two modes -in vivo and ex vivo. In in vivo approach, any viral or non-viral vector with the packaged CRISPR/Cas system is injected directly into the patient body. Whereas, in ex vivo approach, first the cells are extracted from patient body, they are grown in the laboratory set-up where gene editing process is carried out and eventually the genetically altered cells are injected back into the patient body. Apart from this, it is often used in functional genomics field to identify gene targets associated with certain diseases. Researchers can create gRNA libraries that target different genes in cell lines or animals and can further note the disruptions leading to phenotypic changes. This allows identification of candidate target genes involved in disease mechanism as well as potential therapeutic targets. CRISPR also enables high-throughput screening of genes in a fast and efficient manner. It is possible to establish experiments using pooled CRISPR libraries to screen thousands of genes simultaneously to discover gene functions and understand their effects on various biological and pathological processes. Such high-throughput libraries are being constructed and explored particularly in cancers paving the way of using CRISPR in personalized medicine. Furthermore, CRISPR can also be used to create animal models for many diseases helping researchers understand the molecular mechanisms of those diseases and eventually serving as an excellent tool during early-stage drug discovery by enabling identification of therapeutic targets. As of today, numerous CRISPR-based therapeutics are in the pre-clinical stage of development, and many are undergoing clinical trials to validate their safety and efficacy for diverse disease conditions, as discussed further in this article (CRISPR Therapeutics: Candidates in the Developmental Pipeline)). In December 2023, the first CRISPR/Cas9 based gene editing therapy got approval by the US Food and Drug Administration (FDA) for the treatment of patients with transfusion-dependent β-thalassemia. The same therapy was approved in Europe in November 2023 for sickle cell disease and transfusion-dependent β-thalassemia. To gain insight and to understand the current trend in CRISPR therapeutics research, we explored the data from CAS Content Collection TM , and performed a quantitative analysis.